FRO - Grant of synthetic options Frontline plc ("Frontline" or the "Company") hereby announces that 362,284 synthetic options have today been granted to management and employees of the Company. The synthetic options will have a five-year term expiring May 27, 2030, and will vest over a three-year vesting period as follows: 1/3 of the synthetic options will vest on May 27, 20261/3 of the synthetic options will vest on May 27, 2027 1/3 of the synthetic options will vest on May 27, 2028 The exercise price of the synthetic options is USD 16.8 being the volume-weighted average price of the ...
FRO - Q1 2025 Presentation Please find enclosed the presentation of Frontline plc´s first quarter 2025 results to be held on the webcast / conference call 23 May, 2025 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 – 12 of the Norwegian Securities Trading Act. Attachment
FRO – First Quarter 2025 Results FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 Frontline plc (the “Company”, “Frontline,” “we,” “us,” or “our”), today reported unaudited results for the three months ended March 31, 2025: Highlights Profit of $33.3 million, or $0.15 per share for the first quarter of 2025.Adjusted profit of $40.4 million, or $0.18 per share for the first quarter of 2025.Declared a cash dividend of $0.18 per share for the first quarter of 2025.Reported revenues of $427.9 million for the first quarter of 2025.Achieved average daily spot time char...
FRO – Invitation to Q1 2025 Results Conference Call and Webcast Frontline plc.’s preliminary first quarter 2025 results will be released on Friday May 23, 2025, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at ahead of the conference call. In order to attend the conference call you may do one of the following: a. Webcast Go to the Investor Relations section at and follow the “Webcast” link, or access directly from the link below. b. Conference C...
Q1 sales beat our forecast by 5% and adj. EBITA outperformed by 8%. Overall, we believe the highlight in the report was the stronger haemophilia result than expected, with solid growth in Altuvoct and a smaller decline for Elocta than forecast. The weak spot was Vonjo sales, which missed our estimate by 28% and consensus by 29%, with management citing stocking issues. We reiterate our BUY and SEK365 target price.
We believe the tanker fundamentals continue to look attractive, in particular for the VLCCs, with a highly manageable ~4% deliveries expected for 2025–2026. Further, we see potential positive catalysts in sanctions further restricting volumes transported on the dark fleet (possibly triggering scrapping postponed by shadow fleet deployment) and signs of a more aggressive volume strategy from OPEC+. Hence, we reiterate our BUY but have reduced out target price to NOK280 (295).
The Q1 results were mixed, but with the financials now in good order, we see more of a growth focus ahead. We find management’s priorities logical, with our underlying forecast largely unchanged, but our 2025–2027e EPS cut by 6–2% on FX and non-cash items. We reiterate our BUY, but have trimmed our target price to SEK52 (53), focusing on Humana’s market opportunity, operating profile, financial outlook and valuation.
The US Trade Representative on 17 April published revised US port fees with significant changes to the initial proposal based on industry feedback. In its current form, the fees will primarily discourage use of Chinese-controlled maritime trade services to the US, and directly affect the use of Chinese-built vessels in US ports (with several considerable exemptions to avoid harm to US trade). The previous broader fees based on fleet composition and share of Chinese-built vessels has been scrappe...
FRO – Filing of Annual Report Frontline plc (the “Company”) announces the filing of its annual report for the year ended December 31, 2024. The annual report can be downloaded from the Company’s website or from the link below. Additionally, shareholders can request a hard copy of our complete audited financial statements free of charge by writing to us at:John Kennedy 8 Iris Building, 7th floor, Flat/Office 740B,3106, Limassol, Cyprus. or sending an e-mail to April 7, 2025Frontline plcLimassol, Cyprus. Questions should be directed to: Lars H. Barstad: Chief Executive Officer, Front...
We forecast a decent quarter, despite some difficult revenue comparables, with no manufacturing revenues, lower Elocta sales and lower Beyfortus royalties YOY, unlikely to be fully compensated by new product growth, such as for Altuvoct. Meanwhile, the company continues to invest in its recently launched products (and coming launches), which should be well known by the market. We reiterate our BUY and SEK365 target price.
A director at Frontline Plc bought 5,000 shares at 171.050NOK and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
The recurring theme at our 18th Energy & Shipping Conference was geopolitical uncertainty and a potential trade war, warranting a wait-and-see approach, particularly on the Trump 2.0 effect. The consensus view pointed to high asset values, with no rush to the yards, aligning with below-NAV valuations across most of our coverage. However, panellists generally saw less downside risk than the 25% average discount to steel for our Tanker, Dry Bulk and Gas coverage. Overall, the day highlighted uncer...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.